Acurx Pharmaceuticals, Inc. (ACXP)
| Market Cap | 52.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.72M |
| Shares Out | 13.77M |
| EPS (ttm) | -1.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,583 |
| Open | 3.96 |
| Previous Close | 3.97 |
| Day's Range | 3.72 - 3.96 |
| 52-Week Range | 1.17 - 8.82 |
| Beta | -1.87 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+265.54%) |
| Earnings Date | Nov 14, 2023 |
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ACXP stock is "Strong Buy" and the 12-month stock price forecast is $14.0.
News
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure
All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure (CC) at end of treatment (EOT) remained free of C. difficile Infection (CDI) recurrence through one month after EOT, for a S...
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
STATEN ISLAND, N.Y. , Nov. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary efficacy endpoint of the Clinical Cure rate ...
Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update
STATEN ISLAND, N.Y. , Oct. 25, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences
Three scientific posters highlighting novel anti-virulence pharmacologic properties of oral ibezapolstat for C. difficile Infection; effects on toxin production, biofilm and the gut microbiome A podiu...
Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection
Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as expected High rates of Clinical Cure wer...
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress
Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted 36 patients at which point an Interim Ana...
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023
STATEN ISLAND, N.Y. , Aug. 22, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
STATEN ISLAND, N.Y. , Aug. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update
STATEN ISLAND, N.Y. , July 24, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. STATEN ISLAND, N.Y.
Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET
STATEN ISLAND, N.Y. , June 15, 2023 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacter...
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
STATEN ISLAND, N.Y. , May 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti...
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update
STATEN ISLAND, N.Y. , May 12, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti...
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update
STATEN ISLAND, N.Y. , May 5, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...
Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference
A scientific poster highlighting a novel pharmacologic property of oral ibezapolstat for C. difficile Infection likely related to its unique mechanism of action was presented at ECCMID 2023 An update ...
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference
STATEN ISLAND, N.Y. , April 11, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibio...
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
STATEN ISLAND, N.Y. , March 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibio...
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
STATEN ISLAND, N.Y. , March 6, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
CEO Spotlight: Acurx Pharmaceuticals CEO Confident His Phase 2b Ibezapolstat Drug Candidate Can Earn Front-Line Designation to Treat C. difficile
Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficileNew York, New York-...
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference STATEN ISLAND, ...
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update
STATEN ISLAND, N.Y. , Nov. 14, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update
STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti...
Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022
Presents research on ibezapolstat's selective activity on healthy bacteria within the gut microbiome in the treatment of C. difficile Infection (CDI) Emerging ibezapolstat microbiome data demonstrate ...
Acurx Announces Scientific Oral and Poster Presentations at IDWeek
New emerging, favorable microbiome data to be presented from previously completed Ph1 healthy volunteers and Ph2a patients with C. difficile Infection clinical trials Extends research on ibezapolstat'...